MannKind Corporation (MNKD)
USD 5.0
(1.01%)
USD 5.0
(1.01%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 143.89 Million USD | -54.05% |
| 2022 | 313.14 Million USD | 21.11% |
| 2021 | 258.56 Million USD | 358.18% |
| 2020 | 56.43 Million USD | -38.33% |
| 2019 | 91.5 Million USD | 192.08% |
| 2018 | 31.32 Million USD | -72.24% |
| 2017 | 112.87 Million USD | -10.13% |
| 2016 | 125.6 Million USD | 56.16% |
| 2015 | 80.43 Million USD | 212.77% |
| 2014 | -71.32 Million USD | -192.42% |
| 2013 | 77.17 Million USD | -50.33% |
| 2012 | 155.37 Million USD | -67.97% |
| 2011 | 485.16 Million USD | 28.15% |
| 2010 | 378.59 Million USD | 52.81% |
| 2009 | 247.74 Million USD | 116.17% |
| 2008 | 114.6 Million USD | 144.68% |
| 2007 | -256.52 Million USD | -23.16% |
| 2006 | -208.28 Million USD | -271.7% |
| 2005 | -56.03 Million USD | 29.06% |
| 2004 | -78.98 Million USD | -45.95% |
| 2003 | -54.12 Million USD | -171.73% |
| 2002 | -19.91 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 241.58 Million USD | 33.5% |
| 2024 Q1 | 180.96 Million USD | 25.76% |
| 2023 Q4 | 143.89 Million USD | -26.02% |
| 2023 Q1 | 297.03 Million USD | -5.14% |
| 2023 Q2 | 296.97 Million USD | -0.02% |
| 2023 Q3 | 194.51 Million USD | -34.5% |
| 2023 FY | 143.89 Million USD | -54.05% |
| 2022 Q4 | 313.14 Million USD | 33.88% |
| 2022 Q3 | 233.9 Million USD | -7.34% |
| 2022 FY | 313.14 Million USD | 21.11% |
| 2022 Q1 | 224.66 Million USD | -13.11% |
| 2022 Q2 | 252.43 Million USD | 12.36% |
| 2021 Q4 | 258.56 Million USD | 12.52% |
| 2021 Q3 | 229.78 Million USD | 2.96% |
| 2021 Q1 | 83.62 Million USD | 48.18% |
| 2021 FY | 258.56 Million USD | 358.18% |
| 2021 Q2 | 223.17 Million USD | 166.88% |
| 2020 Q2 | 60.36 Million USD | -26.65% |
| 2020 Q4 | 56.43 Million USD | -20.46% |
| 2020 Q1 | 82.3 Million USD | -10.06% |
| 2020 FY | 56.43 Million USD | -38.33% |
| 2020 Q3 | 70.95 Million USD | 17.53% |
| 2019 Q4 | 91.5 Million USD | 0.18% |
| 2019 FY | 91.5 Million USD | 192.08% |
| 2019 Q3 | 91.34 Million USD | -3.96% |
| 2019 Q2 | 95.11 Million USD | 32.89% |
| 2019 Q1 | 71.57 Million USD | 128.45% |
| 2018 FY | 31.32 Million USD | -72.24% |
| 2018 Q1 | 113.56 Million USD | 0.61% |
| 2018 Q4 | 31.32 Million USD | -67.03% |
| 2018 Q3 | 95.03 Million USD | -7.9% |
| 2018 Q2 | 103.18 Million USD | -9.14% |
| 2017 Q3 | 145.17 Million USD | 19.57% |
| 2017 FY | 112.87 Million USD | -10.13% |
| 2017 Q2 | 121.41 Million USD | 20.24% |
| 2017 Q1 | 100.98 Million USD | -19.6% |
| 2017 Q4 | 112.87 Million USD | -22.25% |
| 2016 Q2 | 158.84 Million USD | -17.84% |
| 2016 Q1 | 193.33 Million USD | 140.37% |
| 2016 FY | 125.6 Million USD | 56.16% |
| 2016 Q3 | 156.08 Million USD | -1.73% |
| 2016 Q4 | 125.6 Million USD | -19.53% |
| 2015 Q1 | 101.63 Million USD | 242.51% |
| 2015 Q4 | 80.43 Million USD | -50.36% |
| 2015 Q2 | 144.34 Million USD | 42.02% |
| 2015 Q3 | 162.01 Million USD | 12.24% |
| 2015 FY | 80.43 Million USD | 212.77% |
| 2014 Q2 | 144.94 Million USD | 4.8% |
| 2014 FY | -71.32 Million USD | -192.42% |
| 2014 Q4 | -71.32 Million USD | -246.14% |
| 2014 Q3 | 48.8 Million USD | -66.33% |
| 2014 Q1 | 138.29 Million USD | 79.21% |
| 2013 Q3 | 123.72 Million USD | -59.28% |
| 2013 FY | 77.17 Million USD | -50.33% |
| 2013 Q4 | 77.17 Million USD | -37.63% |
| 2013 Q2 | 303.85 Million USD | -0.05% |
| 2013 Q1 | 304.01 Million USD | 95.66% |
| 2012 FY | 155.37 Million USD | -67.97% |
| 2012 Q2 | 397.68 Million USD | -9.21% |
| 2012 Q3 | 433.05 Million USD | 8.89% |
| 2012 Q4 | 155.37 Million USD | -64.12% |
| 2012 Q1 | 438.04 Million USD | -9.71% |
| 2011 FY | 485.16 Million USD | 28.15% |
| 2011 Q3 | 464.72 Million USD | 8.73% |
| 2011 Q1 | 386.94 Million USD | 2.21% |
| 2011 Q2 | 427.41 Million USD | 10.46% |
| 2011 Q4 | 485.16 Million USD | 4.4% |
| 2010 Q2 | 326.67 Million USD | 13.1% |
| 2010 Q4 | 378.59 Million USD | 4.27% |
| 2010 FY | 378.59 Million USD | 52.81% |
| 2010 Q1 | 288.84 Million USD | 16.59% |
| 2010 Q3 | 363.09 Million USD | 11.15% |
| 2009 Q4 | 247.74 Million USD | 18.7% |
| 2009 FY | 247.74 Million USD | 116.17% |
| 2009 Q3 | 208.71 Million USD | -3.45% |
| 2009 Q2 | 216.17 Million USD | 23.34% |
| 2009 Q1 | 175.26 Million USD | 52.93% |
| 2008 Q4 | 114.6 Million USD | 42.29% |
| 2008 FY | 114.6 Million USD | 144.68% |
| 2008 Q1 | -157.19 Million USD | 38.72% |
| 2008 Q2 | -68.45 Million USD | 56.46% |
| 2008 Q3 | 80.54 Million USD | 217.67% |
| 2007 Q4 | -256.52 Million USD | -530.95% |
| 2007 FY | -256.52 Million USD | -23.16% |
| 2007 Q3 | -40.65 Million USD | 61.24% |
| 2007 Q2 | -104.9 Million USD | 30.69% |
| 2007 Q1 | -151.34 Million USD | 27.34% |
| 2006 FY | -208.28 Million USD | -271.7% |
| 2006 Q3 | 6.91 Million USD | 125.55% |
| 2006 Q4 | -208.28 Million USD | -3112.55% |
| 2006 Q2 | -27.05 Million USD | 41.04% |
| 2006 Q1 | -45.88 Million USD | 18.11% |
| 2005 Q1 | -22.08 Million USD | 72.03% |
| 2005 FY | -56.03 Million USD | 29.06% |
| 2005 Q2 | -19.55 Million USD | 11.49% |
| 2005 Q4 | -56.03 Million USD | 19.07% |
| 2005 Q3 | -69.23 Million USD | -254.12% |
| 2004 Q2 | -37.37 Million USD | 33.39% |
| 2004 Q3 | -103.87 Million USD | -177.93% |
| 2004 Q4 | -78.98 Million USD | 23.96% |
| 2004 Q1 | -56.11 Million USD | 0.0% |
| 2004 FY | -78.98 Million USD | -45.95% |
| 2003 FY | -54.12 Million USD | -171.73% |
| 2002 FY | -19.91 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Absci Corporation | -72.59 Million USD | 298.213% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 12.453% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 92.305% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 191114.681% |
| Apollomics, Inc. | -27.39 Million USD | 625.275% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 22044.855% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 262.671% |
| Bicycle Therapeutics plc | -481.46 Million USD | 129.888% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 211.451% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -297.918% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -3362.44% |
| Chimerix, Inc. | -25.51 Million USD | 663.934% |
| CRISPR Therapeutics AG | -150.84 Million USD | 195.395% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 19.006% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 152.176% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1777.352% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1777.352% |
| Gritstone bio, Inc. | 39.49 Million USD | -264.394% |
| Allakos Inc. | -24.97 Million USD | 676.172% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 768.955% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1696.04% |
| Cytokinetics, Incorporated | 642.37 Million USD | 77.599% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 300.576% |
| Innoviva, Inc. | 255.56 Million USD | 43.693% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 1657.823% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -19449.741% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 454.676% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 2664.922% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 281.409% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 477.272% |
| ImmuCell Corporation | 10.99 Million USD | -1209.296% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 193.352% |
| Incyte Corporation | -3.17 Billion USD | 104.532% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -805.117% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 12211.334% |
| Mustang Bio, Inc. | -3.73 Million USD | 3951.686% |
| MiMedx Group, Inc. | -33.9 Million USD | 524.468% |
| MEI Pharma, Inc. | -3.7 Million USD | 3983.914% |
| MacroGenics, Inc. | -66.98 Million USD | 314.823% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 2080.421% |
| Mereo BioPharma Group plc | -51.46 Million USD | 379.584% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1052.251% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 1508.841% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -299.664% |
| Minerva Neurosciences, Inc. | 41 Million USD | -250.937% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 747.261% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 5769.779% |
| NextCure, Inc. | -6.47 Million USD | 2321.692% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 598.403% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 384.943% |
| Onconetix, Inc. | 5.33 Million USD | -2599.066% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 2355.824% |
| Opthea Limited | 28.15 Million USD | -411.051% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -658.953% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -1987.127% |
| PDS Biotechnology Corporation | -32.7 Million USD | 539.938% |
| Precigen, Inc. | -481 Thousand USD | 30016.632% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 927.196% |
| Prime Medicine, Inc. | -27.94 Million USD | 615.01% |
| PureTech Health plc | -167.19 Million USD | 186.066% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 566.266% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 630.993% |
| Replimune Group, Inc. | 1.41 Million USD | -10091.147% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1299.988% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -417.753% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 6310.502% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 123.66% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 876.998% |
| Sesen Bio, Inc. | -112.55 Million USD | 227.85% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2126.746% |
| Solid Biosciences Inc. | -47.75 Million USD | 401.359% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 148.985% |
| SciSparc Ltd. | -2.06 Million USD | 7068.475% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -26.804% |
| TG Therapeutics, Inc. | 17.86 Million USD | -705.615% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1050.77% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 2417.961% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 58.484% |
| UroGen Pharma Ltd. | 4.39 Million USD | -3177.135% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 698.656% |
| XOMA Corporation | -29 Million USD | 596.203% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -711.384% |
| AbCellera Biologics Inc. | -55.94 Million USD | 357.238% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1138.532% |
| Cassava Sciences, Inc. | -121.13 Million USD | 218.791% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1965.118% |
| Precision BioSciences, Inc. | -85.41 Million USD | 268.48% |
| Dyadic International, Inc. | -6.37 Million USD | 2356.142% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 1813.491% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1003.151% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 572.42% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 532.688% |
| IGM Biosciences, Inc. | -72.6 Million USD | 298.192% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 449.397% |
| Acelyrin, Inc. | -216.9 Million USD | 166.343% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 1686.013% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 957.103% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 1784.374% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 145.424% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 285.794% |
| Senti Biosciences, Inc. | 1.74 Million USD | -8170.057% |
| Mesoblast Limited | 55.96 Million USD | -157.132% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 668.951% |
| ChromaDex Corporation | -24.04 Million USD | 698.382% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 16791.896% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -134.91% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 2034.611% |
| Seer, Inc. | -4.24 Million USD | 3493.844% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 11.032% |
| Novavax, Inc. | -298.29 Million USD | 148.241% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 1674.127% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -133.352% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 3020.028% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 274.465% |
| Celcuity Inc. | 6.78 Million USD | -2021.306% |
| ContextLogic Inc. | -232 Million USD | 162.025% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 159.373% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 230.182% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 96.865% |
| Amarin Corporation plc | -191.04 Million USD | 175.324% |
| AnaptysBio, Inc. | -18.15 Million USD | 892.788% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1350.534% |
| Aptorum Group Limited | 1.35 Million USD | -10503.841% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 318.174% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -3262.126% |
| Ardelyx, Inc. | 34.51 Million USD | -316.954% |
| Celularity Inc. | 65.19 Million USD | -120.738% |
| Omeros Corporation | 331.17 Million USD | 56.549% |
| Humacyte, Inc. | -22.48 Million USD | 739.949% |
| Immunocore Holdings plc | -358.59 Million USD | 140.129% |
| IO Biotech, Inc. | -140.69 Million USD | 202.274% |
| GT Biopharma, Inc. | -1.02 Million USD | 14193.928% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 176.453% |
| Summit Therapeutics Inc. | 34.67 Million USD | -315.005% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 2473.788% |
| Pulmatrix, Inc. | -10.41 Million USD | 1481.386% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 229.171% |
| Evogene Ltd. | -19.63 Million USD | 832.907% |
| CorMedix Inc. | -43.05 Million USD | 434.241% |
| BioLineRx Ltd. | 7.33 Million USD | -1861.546% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 222.942% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 291.676% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 180.402% |
| scPharmaceuticals Inc. | -6.54 Million USD | 2298.61% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1076.116% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 206.277% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -19449.741% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 876.998% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 169.128% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 255.125% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 745.634% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 177.949% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 639.776% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -1083.062% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 962.075% |
| Daré Bioscience, Inc. | -5.15 Million USD | 2889.87% |
| bluebird bio, Inc. | 108.57 Million USD | -32.539% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 62.007% |
| DBV Technologies S.A. | -126.98 Million USD | 213.319% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 182.12% |
| Galecto, Inc. | -21.21 Million USD | 778.257% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 2215.229% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 256.872% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 312.294% |
| GlycoMimetics, Inc. | -40.98 Million USD | 451.107% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -23.42% |
| ADMA Biologics, Inc. | 90.06 Million USD | -59.771% |
| Clene Inc. | 3.34 Million USD | -4208.353% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 141.816% |
| Aptose Biosciences Inc. | -8.19 Million USD | 1855.967% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 4698.855% |
| Soligenix, Inc. | -4.95 Million USD | 3006.113% |
| Century Therapeutics, Inc. | 847 Thousand USD | -16889.256% |
| Kura Oncology, Inc. | -20.11 Million USD | 815.275% |
| Surrozen, Inc. | -32.66 Million USD | 540.543% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 451.608% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -7799.182% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 4601.063% |
| Autolus Therapeutics plc | -186.59 Million USD | 177.117% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 391.861% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -319.922% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 707.759% |
| GRI Bio, Inc. | -1.79 Million USD | 8121.126% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 1701.895% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -2596.253% |
| INmune Bio, Inc. | -25.41 Million USD | 666.286% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 4.672% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 384.054% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 985.567% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 1648.762% |
| Jaguar Health, Inc. | 29.39 Million USD | -389.602% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 5087.962% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -278.532% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -921.937% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -351.306% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 61.927% |
| Verastem, Inc. | -37.27 Million USD | 486.016% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 377.465% |
| Histogen Inc. | -7.48 Million USD | 2021.985% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 765.989% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 209.469% |
| Surrozen, Inc. | -32.66 Million USD | 540.543% |
| Organovo Holdings, Inc. | -1.5 Million USD | 9648.706% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 3523.324% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 1816.936% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 431.244% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1087.174% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 20028.953% |
| Kronos Bio, Inc. | -36.05 Million USD | 499.121% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1086.691% |
| Synaptogenix, Inc. | -28.66 Million USD | 602.064% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 15473.825% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -22813.854% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -195.286% |
| Exelixis, Inc. | -73.05 Million USD | 296.987% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 699.255% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 159.617% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 271.103% |
| ESSA Pharma Inc. | -33.62 Million USD | 527.996% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 5566.996% |
| Avid Bioservices, Inc. | 169.72 Million USD | 15.218% |
| Insmed Incorporated | 721.62 Million USD | 80.059% |
| MediWound Ltd. | -5.32 Million USD | 2803.852% |
| OmniAb, Inc. | 9.2 Million USD | -1463.61% |
| Alector, Inc. | -35.63 Million USD | 503.791% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -67.381% |
| Zai Lab Limited | -775 Million USD | 118.568% |
| AlloVir, Inc. | -62.69 Million USD | 329.533% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 57.746% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 1192.544% |
| Aura Biosciences, Inc. | -21.52 Million USD | 768.52% |
| Immunic, Inc. | -45.34 Million USD | 417.378% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 174.476% |
| Veracyte, Inc. | -203.82 Million USD | 170.6% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 77.456% |
| FibroGen, Inc. | 56.76 Million USD | -153.491% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1515.935% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 207.324% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 5190.019% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 7050.474% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 4407.064% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 186.705% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 90.831% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 688.015% |
| XBiotech Inc. | -200.02 Million USD | 171.941% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 271.103% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 145.437% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 8446.81% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -3077.981% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 508.074% |
| Agenus Inc. | 274.13 Million USD | 47.508% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 286.354% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -2428.536% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 184.44% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 255.779% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 80.456% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 1436.413% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 358.746% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 4267.756% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 1703.143% |
| Lantern Pharma Inc. | -21.7 Million USD | 763.029% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 3502.672% |
| Ainos, Inc. | 4.07 Million USD | -3428.728% |
| Pluri Inc. | 22.82 Million USD | -530.334% |
| Prothena Corporation plc | -608.34 Million USD | 123.654% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 221.172% |
| Rallybio Corporation | -24.1 Million USD | 697.042% |
| Kodiak Sciences Inc. | -103.87 Million USD | 238.531% |
| Cue Biopharma, Inc. | -33.81 Million USD | 525.498% |
| MeiraGTx Holdings plc | -40.3 Million USD | 457.052% |
| Annexon, Inc. | -193.75 Million USD | 174.269% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 922.327% |
| Moderna, Inc. | -2.9 Billion USD | 104.95% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 685.55% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 565.677% |
| Blueprint Medicines Corporation | 702.83 Million USD | 79.526% |
| Immix Biopharma, Inc. | -17.5 Million USD | 921.82% |
| CalciMedica, Inc. | -5.53 Million USD | 2702.152% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 275.354% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 459.415% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 185.536% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 532.74% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 2507.546% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 340.056% |
| Nutriband Inc. | -251.65 Thousand USD | 57280.607% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 521.756% |
| Vor Biopharma Inc. | 4.3 Million USD | -3246.488% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 102.384% |
| Alkermes plc | -166.73 Million USD | 186.302% |
| ProKidney Corp. | -56.23 Million USD | 355.884% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 395.65% |
| Arcellx, Inc. | -296.95 Million USD | 148.458% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 89.449% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 623.936% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -211.827% |
| Atai Life Sciences N.V. | -28.55 Million USD | 603.883% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -6351.34% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 730.693% |
| MediciNova, Inc. | -50.78 Million USD | 383.358% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 282.601% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 639793.265% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2330.097% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 172.014% |
| Biomea Fusion, Inc. | -166.57 Million USD | 186.39% |
| RenovoRx, Inc. | -1.17 Million USD | 12367.604% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 251.722% |
| Geron Corporation | 14.76 Million USD | -874.859% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3051.533% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 161.381% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 252.741% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 250.371% |
| Royalty Pharma plc | 5.65 Billion USD | 97.457% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 468.282% |
| Imunon, Inc. | -4.21 Million USD | 3514.904% |
| BioAtla, Inc. | -109.01 Million USD | 232.004% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -1102.566% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 778.673% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 202.251% |
| Structure Therapeutics Inc. | -124.33 Million USD | 215.731% |
| 89bio, Inc. | -289.05 Million USD | 149.783% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 968.955% |
| aTyr Pharma, Inc. | -7.44 Million USD | 2031.79% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 215.455% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 275.961% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 16848.333% |
| Akari Therapeutics, Plc | -3.84 Million USD | 3842.497% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -8766.836% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 89.579% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -72.13% |
| Liquidia Corporation | -80.17 Million USD | 279.479% |
| Entera Bio Ltd. | -10.62 Million USD | 1453.834% |
| GH Research PLC | -78.07 Million USD | 284.304% |
| Vericel Corporation | 1.27 Million USD | -11168.52% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 919.284% |
| Xencor, Inc. | 29.64 Million USD | -385.424% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 7405.215% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 985.567% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 58856.349% |
| Vaxcyte, Inc. | -368.22 Million USD | 139.079% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 204.471% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 213.829% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 12211.334% |
| Portage Biotech Inc. | -4.98 Million USD | 2988.958% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 639793.265% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 317.627% |
| OncoCyte Corporation | -6.56 Million USD | 2292.58% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -15934.869% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 3258.698% |
| Purple Biotech Ltd. | -14.13 Million USD | 1117.817% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 874.942% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 2555.614% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 344.639% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 705.737% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 726.301% |
| United Therapeutics Corporation | -507.7 Million USD | 128.343% |
| HilleVax, Inc. | -165.48 Million USD | 186.956% |
| Silo Pharma, Inc. | -3.52 Million USD | 4183.043% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -144132.176% |
| Pharming Group N.V. | 109.8 Million USD | -31.051% |
| Tharimmune, Inc. | -10.93 Million USD | 1415.906% |
| Genprex, Inc. | -6.73 Million USD | 2235.751% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 223.75% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 139.017% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -1311.466% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 10371.163% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 4438.298% |
| OKYO Pharma Limited | -826.84 Thousand USD | 17503.32% |
| Savara Inc. | 153 Thousand USD | -93951.634% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1050.18% |
| Curis, Inc. | -23.88 Million USD | 702.416% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 18643.399% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -12043.376% |
| BeiGene, Ltd. | -2.25 Billion USD | 106.387% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 177.538% |
| Erasca, Inc. | -37.21 Million USD | 486.659% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 11273.211% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 11273.211% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 1490.06% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 1424.061% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 558.701% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 545.894% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 518.603% |
| Adicet Bio, Inc. | -138.78 Million USD | 203.683% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 27.348% |
| Aditxt, Inc. | 18.12 Million USD | -694.106% |
| Adagene Inc. | -87.62 Million USD | 264.217% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 3554.603% |
| Quantum-Si incorporated | -118.55 Million USD | 221.375% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 2025.279% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 396.644% |
| Compugen Ltd. | -12.9 Million USD | 1215.15% |
| Generation Bio Co. | 31.44 Million USD | -357.578% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 182.057% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 565.346% |
| Invivyd, Inc. | -198.47 Million USD | 172.502% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 259.41% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 6101.573% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 303.276% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 2208.41% |
| 2seventy bio, Inc. | 181.71 Million USD | 20.811% |
| Instil Bio, Inc. | 75.35 Million USD | -90.954% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 1684.319% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 4717.532% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2330.097% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 653.464% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 3616.966% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 2862.507% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 210.433% |
| Evaxion Biotech A/S | 5.28 Million USD | -2621.832% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 227.833% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 209.618% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 379.361% |
| Cingulate Inc. | 3.08 Million USD | -4567.979% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 4999.523% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1902.212% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 236.343% |
| Clearmind Medicine Inc. | -3.94 Million USD | 3749.816% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -1429.376% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -9768.756% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 365.222% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -732.845% |
| ImmunityBio, Inc. | 618.22 Million USD | 76.724% |
| Korro Bio, Inc. | -132.94 Million USD | 208.241% |
| Kineta, Inc. | -4.54 Million USD | 3268.884% |
| BioVie Inc. | -17.73 Million USD | 911.505% |
| Codexis, Inc. | -43.27 Million USD | 432.553% |
| Celularity Inc. | 65.19 Million USD | -120.738% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -94.143% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 4640.833% |
| Virax Biolabs Group Limited | -3.36 Million USD | 4376.416% |
| Cibus, Inc. | -8.07 Million USD | 1881.369% |
| IN8bio, Inc. | -16.38 Million USD | 978.022% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -399619.444% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 4196.186% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 86.351% |
| Eyenovia, Inc. | 1.25 Million USD | -11332.333% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -434.841% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 4537.219% |
| Elevation Oncology, Inc. | -19.11 Million USD | 852.689% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 532.818% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 837.717% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 344.414% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 794.259% |
| Moolec Science SA | 117.61 Thousand USD | -122246.449% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 474.747% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 479.501% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 201.752% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 739.693% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 2158.811% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 2783.252% |
| Humacyte, Inc. | -22.48 Million USD | 739.949% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 670.078% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 8170.611% |
| Genelux Corporation | -6.89 Million USD | 2185.795% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 563.309% |
| Notable Labs, Ltd. | -9.77 Million USD | 1571.962% |
| Immunovant, Inc. | -635.22 Million USD | 122.653% |
| Quantum-Si incorporated | -118.55 Million USD | 221.375% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 3573.304% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -1692.687% |
| Acasti Pharma Inc. | -23 Million USD | 725.512% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 4373.514% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 185.008% |
| PepGen Inc. | -60.67 Million USD | 337.183% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 852.374% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 16791.896% |
| Immuneering Corporation | -54.94 Million USD | 361.907% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 3523.324% |
| Belite Bio, Inc | -87.27 Million USD | 264.888% |
| XOMA Corporation | -29 Million USD | 596.203% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 303.543% |
| Bionomics Limited | 227 Million USD | 36.611% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 5780.971% |
| uniQure N.V. | -102.95 Million USD | 239.774% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 3554.603% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -251.393% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1303.068% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 4750.604% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -135653.774% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 4537.219% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1515.935% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 2040.386% |
| Altimmune, Inc. | -134.48 Million USD | 206.998% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 177.574% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 5780.971% |
| Peak Bio, Inc. | 10.34 Million USD | -1291.652% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 50947.703% |
| Benitec Biopharma Inc. | -50.58 Million USD | 384.487% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 237.916% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -632.497% |
| Zura Bio Limited | -99.8 Million USD | 244.179% |
| PolyPid Ltd. | 6.17 Million USD | -2232.237% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -632.497% |
| argenx SE | -2.02 Billion USD | 107.093% |
| Immunome, Inc. | -97.02 Million USD | 248.305% |
| Verona Pharma plc | -220.44 Million USD | 165.277% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 300.576% |
| Shattuck Labs, Inc. | -121.42 Million USD | 218.51% |
| CervoMed Inc. | -7.79 Million USD | 1946.553% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 3390.624% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 209.23% |
| Moolec Science SA | 117.61 Thousand USD | -122246.449% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 6389.355% |
| Design Therapeutics, Inc. | -18.15 Million USD | 892.832% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 304.457% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -1181.152% |
| Achilles Therapeutics plc | -126.92 Million USD | 213.374% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -9768.756% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 2034.126% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 57.701% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -506.273% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 132.158% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 202.557% |
| Beam Therapeutics Inc. | -262.72 Million USD | 154.772% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -559.603% |
| AEON Biopharma, Inc. | -4.88 Million USD | 3048.75% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 357.588% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 244.101% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 6229.118% |
| NeurAxis, Inc. | 145.7 Thousand USD | -98663.898% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 468.726% |
| Lumos Pharma, Inc. | -28.49 Million USD | 605.033% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 792.694% |
| Palisade Bio, Inc. | -12.06 Million USD | 1292.896% |
| Nutriband Inc. | -251.65 Thousand USD | 57280.607% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 272.785% |
| Neurogene Inc. | -131.95 Million USD | 209.052% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 3031.33% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 138.15% |
| Athira Pharma, Inc. | -88.99 Million USD | 261.686% |
| HCW Biologics Inc. | 2.85 Million USD | -4937.288% |
| XOMA Corporation | -29 Million USD | 596.203% |
| Nektar Therapeutics | 210.24 Million USD | 31.555% |
| Arvinas, Inc. | -313.8 Million USD | 145.857% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -8766.836% |
| Merus N.V. | -192.88 Million USD | 174.604% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -139.892% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 2174.07% |
| Rezolute, Inc. | -68.16 Million USD | 311.095% |
| Clene Inc. | 3.34 Million USD | -4208.353% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 1191.219% |
| BeyondSpring Inc. | -13.75 Million USD | 1146.158% |
| Synlogic, Inc. | -6.68 Million USD | 2252.565% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -12589.506% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 1801.94% |
| Peak Bio, Inc. | 10.34 Million USD | -1291.652% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 274.592% |
| Krystal Biotech, Inc. | -350.23 Million USD | 141.087% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -15.931% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 185.149% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 4657.885% |
| Ikena Oncology, Inc. | -109.15 Million USD | 231.829% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 2000.66% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 534.74% |
| Gossamer Bio, Inc. | 180.35 Million USD | 20.213% |
| CohBar, Inc. | -5.93 Million USD | 2526.328% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 583.727% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3051.533% |
| Legend Biotech Corporation | -949.39 Million USD | 115.157% |
| Mural Oncology plc | -255.84 Million USD | 156.245% |
| Disc Medicine, Inc. | -358.28 Million USD | 140.164% |
| Champions Oncology, Inc. | 4.81 Million USD | -2890.42% |
| REGENXBIO Inc. | 54.76 Million USD | -162.743% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 53612.553% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 195.282% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 1696.748% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 278.351% |
| Vaxart, Inc. | -8.24 Million USD | 1846.135% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 386.766% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 213.159% |
| Cellectis S.A. | -43.85 Million USD | 428.125% |
| Longeveron Inc. | -2.9 Million USD | 5048.384% |
| Repare Therapeutics Inc. | -107.85 Million USD | 233.415% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 85.14% |
| Inozyme Pharma, Inc. | 12 Million USD | -1098.759% |
| Revolution Medicines, Inc. | -608.2 Million USD | 123.66% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 11799.106% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 154.278% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 195.887% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1019.659% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 19545.811% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.505% |
| Denali Therapeutics Inc. | -74.86 Million USD | 292.211% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1299.988% |
| Veru Inc. | 4.77 Million USD | -2910.459% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1379.557% |
| Cingulate Inc. | 3.08 Million USD | -4567.979% |
| Passage Bio, Inc. | 4.58 Million USD | -3038.473% |
| Context Therapeutics Inc. | -14.44 Million USD | 1095.853% |
| Exicure, Inc. | 5.84 Million USD | -2360.233% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 162.463% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 463.657% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -817.08% |
| Nuvalent, Inc. | -335.38 Million USD | 142.905% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -8197.042% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 293.2% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 1718.661% |
| OmniAb, Inc. | 9.2 Million USD | -1463.61% |
| Anew Medical, Inc. | 1.43 Million USD | -9945.551% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -778.41% |
| Lipocine Inc. | -4.75 Million USD | 3126.527% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 231.022% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -844.777% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 384.054% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -478.093% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 2241.036% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 318.602% |
| Ocugen, Inc. | -32.52 Million USD | 542.48% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 268.155% |
| Q32 Bio Inc. | -37.94 Million USD | 479.2% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 23013.854% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1163.634% |
| Equillium, Inc. | -22.39 Million USD | 742.636% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 662.809% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 541.046% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 58143.684% |
| Dominari Holdings Inc. | 195 Thousand USD | -73694.359% |
| Edesa Biotech, Inc. | -5.26 Million USD | 2832.133% |
| vTv Therapeutics Inc. | -8.91 Million USD | 1713.76% |
| Bio-Techne Corporation | 267.74 Million USD | 46.256% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 987.772% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 221.851% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 1812.472% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 1237.452% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 158.706% |
| Nkarta, Inc. | 57.29 Million USD | -151.137% |
| BioCardia, Inc. | 212 Thousand USD | -67776.887% |
| Iterum Therapeutics plc | 13.43 Million USD | -970.836% |